No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

Antoinette Hollestelle, Frederieke H van der Baan, Andrew Berchuck, Sharon E Johnatty, Katja K Aben, Bjarni A Agnarsson, Kristiina Aittomäki, Elisa Alducci, Irene L Andrulis, Hoda Anton-Culver, Natalia N Antonenkova, Antonis C Antoniou, Carmel Apicella, Volker Arndt, Norbert Arnold, Banu K Arun, Brita Arver, Alan Ashworth, Laura Baglietto, Rosemary BalleineElisa V Bandera, Daniel Barrowdale, Yukie T Bean, Lars Beckmann, Matthias W Beckmann, Javier Benitez, Andreas Berger, Raanan Berger, Benoit Beuselinck, Maria Bisogna, Line Bjorge, Carl Blomqvist, Natalia V Bogdanova, Anders Bojesen, Stig E Bojesen, Manjeet K Bolla, Bernardo Bonanni, Judith S Brand, Hiltrud Brauch, Hermann Brenner, Louise Brinton, Angela Brooks-Wilson, Fiona Bruinsma, Joan Brunet, Thomas Brüning, Agnieszka Budzilowska, Clareann H Bunker, Barbara Burwinkel, Ralf Butzow, Inge Sokilde Pedersen, Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2

Publikation: Bidrag til tidsskriftReview (oversigtsartikel)peer review

10 Citationer (Scopus)
OriginalsprogEngelsk
TidsskriftGynecologic Oncology
Vol/bind141
Udgave nummer2
Sider (fra-til)386-401
Antal sider16
ISSN0090-8258
DOI
StatusUdgivet - 2016

Fingeraftryk

Dyk ned i forskningsemnerne om 'No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer'. Sammen danner de et unikt fingeraftryk.

Citationsformater